SUSAN WAYT: Open Payments
NPI 1952428237 · WEST COLUMBIA, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,719 in 116 payments from 22 companies in 2025. Trend: 2023 $1,633 · 2024 $1,767 · 2025 $2,719
Food & beverage: $2,719
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 19 | $699 |
| ABBVIE INC. | 19 | $349 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $221 |
| Novo Nordisk Inc | 6 | $220 |
| GlaxoSmithKline, LLC. | 10 | $163 |
| Astellas Pharma US Inc | 3 | $133 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $132 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $89 |
| Xeris Pharmaceuticals, Inc. | 4 | $83 |
| Otsuka America Pharmaceutical, Inc. | 4 | $82 |
Products named: BREZTRI, CAPLYTA, FARXIGA, VRAYLAR, TRELEGY ELLIPTA, AIRSUPRA, Veozah, Kerendia.
Industry payments across SC — which companies pay providers there.
